These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 19326567)

  • 1. Methamphetamine-induced dopaminergic deficits and refractoriness to subsequent treatment.
    Hanson JE; Birdsall E; Seferian KS; Crosby MA; Keefe KA; Gibb JW; Hanson GR; Fleckenstein AE
    Eur J Pharmacol; 2009 Apr; 607(1-3):68-73. PubMed ID: 19326567
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Methamphetamine self-administration causes persistent striatal dopaminergic alterations and mitigates the deficits caused by a subsequent methamphetamine exposure.
    McFadden LM; Hadlock GC; Allen SC; Vieira-Brock PL; Stout KA; Ellis JD; Hoonakker AJ; Andrenyak DM; Nielsen SM; Wilkins DG; Hanson GR; Fleckenstein AE
    J Pharmacol Exp Ther; 2012 Feb; 340(2):295-303. PubMed ID: 22034657
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Age-dependent differences in dopamine transporter and vesicular monoamine transporter-2 function and their implications for methamphetamine neurotoxicity.
    Volz TJ; Farnsworth SJ; Rowley SD; Hanson GR; Fleckenstein AE
    Synapse; 2009 Feb; 63(2):147-51. PubMed ID: 19021208
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reduced striatal vesicular monoamine transporters after neurotoxic but not after behaviorally-sensitizing doses of methamphetamine.
    Frey K; Kilbourn M; Robinson T
    Eur J Pharmacol; 1997 Sep; 334(2-3):273-9. PubMed ID: 9369358
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Methamphetamine alters vesicular monoamine transporter-2 function and potassium-stimulated dopamine release.
    Chu PW; Hadlock GC; Vieira-Brock P; Stout K; Hanson GR; Fleckenstein AE
    J Neurochem; 2010 Oct; 115(2):325-32. PubMed ID: 20649837
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Methamphetamine administration reduces hippocampal vesicular monoamine transporter-2 uptake.
    Rau KS; Birdsall E; Volz TJ; Riordan JA; Baucum AJ; Adair BP; Bitter R; Gibb JW; Hanson GR; Fleckenstein AE
    J Pharmacol Exp Ther; 2006 Aug; 318(2):676-82. PubMed ID: 16687477
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Age-dependent methamphetamine-induced alterations in vesicular monoamine transporter-2 function: implications for neurotoxicity.
    Truong JG; Wilkins DG; Baudys J; Crouch DJ; Johnson-Davis KL; Gibb JW; Hanson GR; Fleckenstein AE
    J Pharmacol Exp Ther; 2005 Sep; 314(3):1087-92. PubMed ID: 15901804
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bupropion increases striatal vesicular monoamine transport.
    Rau KS; Birdsall E; Hanson JE; Johnson-Davis KL; Carroll FI; Wilkins DG; Gibb JW; Hanson GR; Fleckenstein AE
    Neuropharmacology; 2005 Nov; 49(6):820-30. PubMed ID: 16005476
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential regional effects of methamphetamine on dopamine transport.
    Chu PW; Seferian KS; Birdsall E; Truong JG; Riordan JA; Metcalf CS; Hanson GR; Fleckenstein AE
    Eur J Pharmacol; 2008 Aug; 590(1-3):105-10. PubMed ID: 18599036
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Methylphenidate alters vesicular monoamine transport and prevents methamphetamine-induced dopaminergic deficits.
    Sandoval V; Riddle EL; Hanson GR; Fleckenstein AE
    J Pharmacol Exp Ther; 2003 Mar; 304(3):1181-7. PubMed ID: 12604695
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Methamphetamine rapidly decreases vesicular dopamine uptake.
    Brown JM; Hanson GR; Fleckenstein AE
    J Neurochem; 2000 May; 74(5):2221-3. PubMed ID: 10800970
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An acute, epitope-specific modification in the dopamine transporter associated with methamphetamine-induced neurotoxicity.
    Fricks-Gleason AN; German CL; Hoonakker AJ; Friend DM; Ganesh KK; Carver AS; Hanson GR; Fleckenstein AE; Keefe KA
    Synapse; 2016 Apr; 70(4):139-46. PubMed ID: 26799527
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tamoxifen protects male mice nigrostriatal dopamine against methamphetamine-induced toxicity.
    Bourque M; Liu B; Dluzen DE; Di Paolo T
    Biochem Pharmacol; 2007 Nov; 74(9):1413-23. PubMed ID: 17825264
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Methamphetamine-induced dopamine transporter complex formation and dopaminergic deficits: the role of D2 receptor activation.
    Hadlock GC; Chu PW; Walters ET; Hanson GR; Fleckenstein AE
    J Pharmacol Exp Ther; 2010 Oct; 335(1):207-12. PubMed ID: 20622144
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prior methamphetamine self-administration attenuates the dopaminergic deficits caused by a subsequent methamphetamine exposure.
    McFadden LM; Vieira-Brock PL; Hanson GR; Fleckenstein AE
    Neuropharmacology; 2015 Jun; 93():146-54. PubMed ID: 25645392
    [TBL] [Abstract][Full Text] [Related]  

  • 16. GZ-11608, a Vesicular Monoamine Transporter-2 Inhibitor, Decreases the Neurochemical and Behavioral Effects of Methamphetamine.
    Lee NR; Zheng G; Leggas M; Janganati V; Nickell JR; Crooks PA; Bardo MT; Dwoskin LP
    J Pharmacol Exp Ther; 2019 Nov; 371(2):526-543. PubMed ID: 31413138
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Methamphetamine self-administration acutely decreases monoaminergic transporter function.
    McFadden LM; Stout KA; Vieira-Brock PL; Allen SC; Nielsen SM; Wilkins DG; Hanson GR; Fleckenstein AE
    Synapse; 2012 Mar; 66(3):240-5. PubMed ID: 22120988
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human immunodeficiency virus-1 Tat protein and methamphetamine interact synergistically to impair striatal dopaminergic function.
    Maragos WF; Young KL; Turchan JT; Guseva M; Pauly JR; Nath A; Cass WA
    J Neurochem; 2002 Nov; 83(4):955-63. PubMed ID: 12421368
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Methamphetamine-induced alterations in monoamine transport: implications for neurotoxicity, neuroprotection and treatment.
    Volz TJ; Fleckenstein AE; Hanson GR
    Addiction; 2007 Apr; 102 Suppl 1():44-8. PubMed ID: 17493052
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alterations in vesicular dopamine uptake contribute to tolerance to the neurotoxic effects of methamphetamine.
    Johnson-Davis KL; Truong JG; Fleckenstein AE; Wilkins DG
    J Pharmacol Exp Ther; 2004 May; 309(2):578-86. PubMed ID: 14747615
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.